JUBILANT-DRAXIMAGE
Jubilant DraxImage Inc. (“DraxImage”) is pleased to announce delivery of the first commercial shipment of HICON® Sodium Iodine I-131 Solution USP today to Bogota, Colombia.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151009005056/en/
“This marks a significant milestone for the company as we begin to expand the geographic reach of this important thyroid ablation therapy to physicians and their patients in South America” indicated DraxImage’s President Martyn Coombs.
HICON® Sodium Iodine I-131 Solution is indicated for the treatment of thyroid diseases, such as hyperthyroidism and thyroid cancer. Patients who suffer from these thyroid conditions will now have access to INVIMA-approved Radioiodine therapy. INVIMA is the Colombian Pharmaceutical Regulatory agency. Using DraxImage’s proprietary Smart-FillTM dispensing system, our local distributor, COMCI , will deliver customized, patient-specific I-131 therapeutic capsules to patients requiring treatment for their thyroid disease. This is particularly important given the growing number of thyroid cancers being diagnosed. Specifically, there are almost 2,500 newly diagnosed cases of thyroid cancer every year in Colombia, affecting predominantly women between 25 and 65 years of age.
As the leading manufacturer and supplier of I-131 in North America and the only FDA-approved I-131 bulk solution which allows individualized therapeutic, patient specific doses, Jubilant DraxImage continues its commitment to delivering high quality, reliable, pharmaceutical-grade radioactive iodine to the global market.
In closing, DraxImage President Martyn Coombs stated, “We are very pleased to enter this important South American market with HICON® and Smart-FillTM and look forward to expanding in other areas of the region in the future. More importantly, we are especially proud to bring these essential treatment options to patients in Colombia.”
About Jubilant DraxImage
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences,
develops, manufactures and commercializes radiopharmaceuticals used for
the diagnosis and treatment of disease. The company is dedicated to
nuclear medicine and serves customers and through them patients,
globally, with high quality and reliable products and services. The
company is the market leader in North America for I-131 products
(diagnosis and treatment of thyroid disorder and cancer), MAA (lung
perfusion imaging), DTPA (renal imaging) and MDP (bone imaging), and
also markets other products such as Sestamibi (myocardial perfusion
imaging) and Gluceptate (brain and renal imaging). The company has a
strong development pipeline of new products, notably a Rubidium-82
Generator (PET Cardiology).
www.draximage.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151009005056/en/
Contact:
Jubilant DraxImage
Suzanne Bissonnette, +1 888-633-5343
Director,
Marketing
sbissonnette@jdi.jubl.com
or
Celia
Correa, +1 888-633-5343
Director, Commercial Operations Latin
America
ccorrea@jdi.jubl.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
SmartStream Brings AI-Powered Data Management to the Insurance Sector12.6.2025 09:00:00 CEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) and solutions provider, has announced the expansion of its AI-driven reconciliation and data management platform, SmartStream Air, into the insurance sector. This move aims to help insurers tackle fragmented data challenges, reduce operational costs, and strengthen compliance through robust audit trails. As the insurance industry struggles with limited digital maturity, it faces mounting pressure from increasing transaction volumes, persistent data quality issues, and the complex demands of evolving regulations such as IFRS 17 and DORA. In this environment, the need for advanced, rapidly deployable SaaS data management solutions has never been more urgent. Addressing these challenges requires a fundamental transformation in how insurers manage systems, streamline operations, and ensure data integrity across the enterprise. SmartStream Air leverages cutting-edge AI to reconcile and manage high volumes of data, for exampl
Westlake Epoxy Announces Strategic Collaboration With Alpha Recyclage Composites to Advance Composites Recycling12.6.2025 08:00:00 CEST | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy will collaborate with Alpha Recyclage Composites to support them in scaling up the recycling capacity for carbon fiber composite materials. This collaboration will provide support to Westlake’s composite customers in their development of improved circular options for both production (scrap or off spec composite materials that otherwise become waste) and end-of-life waste. The recovery of the carbon fibers from composite materials for reuse in new or emerging applications aims to establish a more sustainable alternative to traditional disposal methods such as landfilling and incineration. Alpha Recyclage Composites, a family-owned company based in Toulouse and Castelsarrasin, France, specializes in recycling carbon-fibers-reinforced composites through a patented steam pyrolysis process. This innovative technology preserves the performance qualities of the carbon fibers used in composite materials recovered from applica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom